Merck Animal Health has introduced the Circumvent CL vaccine, made to protect pigs aged three weeks and older from diseases caused by Porcine Circovirus Types 2a and 2d and Lawsonia intracellularis.
The Circumvent CL vaccine is ready to use, which means it doesn’t need mixing or reconstituting, making it simple for farmers as well as veterinarians to use. This new vaccine adds to Merck’s existing Circumvent line of vaccines, which has the Circumvent CML vaccine, which protects against similar diseases but also includes protection against Mycoplasma hyopneumoniae.
Key offerings of Circumvent CL include:
- Dual protection: Safeguards pigs from diseases caused by Porcine Circovirus Types 2a and 2d, as well as Lawsonia intracellularis.
- Ready-to-use: No mixing required, saving time along with reducing the chance of errors.
- Flexible options: Ideal for herds that don’t need protection against Mycoplasma hyopneumoniae, offering a more targeted solution for these herds.
- Complementary product: Fits well with other products in the Circumvent vaccine family, giving veterinarians more choices based on specific herd health needs.
Circumvent CL is available in 50- and 250-dose bottles, with a 500-dose version coming in early 2026.
Executive Statement
According to Brett O’Brien, V.M.D., swine technical services, Merck Animal Health, Merck Animal Health is committed to delivering innovative, practical solutions that help veterinarians and producers protect herd health while streamlining on-farm operations. CIRCUMVENT CL provides trusted protection against two of the most significant enteric and systemic disease agents impacting swine production in a ready-to-use formulation. By offering options such as CIRCUMVENT CML and CIRCUMVENT CL, they enable tailored vaccination strategies that simplify vaccine handling and administration.